An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?
subject: mTOR, Everolimus, immune regulation, hyper-activation, COVID-19
creator: Giuseppe Terrazzano, Angela Giovazzino, Valentina Rubino, Anna Teresa Palatucci, Giuseppina Ruggiero, Flavia Carriero
source: Frontiers in Pharmacology
publisher: Frontiers Media S.A.
date: 2020
identifier: DOI: 10.3389/fphar.2020.00856
coverage: Therapeutics. Pharmacology